clinical trial · NCT05450198
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
Merck Sharp & Dohme LLC·phase1·completed·n = 72
Dermatitis, AtopicMK-6194Placebo
brief summary
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
started
Aug 8, 2022
primary completion
May 22, 2024
completion
May 22, 2024
last updated
Jun 5, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol